A pathway toward clinical translation of hyperpolarized [1,4-13C2,2,3-d2]fumarate as an imaging biomarker for early cellular necrosis in vivo.
Saved in:
| Title: | A pathway toward clinical translation of hyperpolarized [1,4-13C |
|---|---|
| Authors: | Birchall JR; Department of Radiology, University of Cambridge, Cambridge, UK., Wodtke P; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK., Grimmer A; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK., Hansen ESS; Department of Clinical Medicine, Aarhus University MR Research Centre, Aarhus, Denmark., Bertelsen LB; Department of Clinical Medicine, Aarhus University MR Research Centre, Aarhus, Denmark., Bøgh N; Department of Clinical Medicine, Aarhus University MR Research Centre, Aarhus, Denmark., Wylot M; Department of Radiology, University of Cambridge, Cambridge, UK., Zamora-Morales MJ; Department of Radiology, University of Cambridge, Cambridge, UK., Arponen O; Department of Radiology, University of Cambridge, Cambridge, UK.; Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland., Horvat-Menih I; Department of Radiology, University of Cambridge, Cambridge, UK., Latimer EC; Department of Radiology, University of Cambridge, Cambridge, UK., Tan F; Radiopharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Pappa E; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK., Graggaber J; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Cheriyan J; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Holmes K; Cancer Research UK Cambridge Centre, Cambridge, UK., Locke MJ; Department of Radiology, University of Cambridge, Cambridge, UK., Sladen H; Cancer Research UK Cambridge Centre, Cambridge, UK., Boren J; The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK., Kettunen MI; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.; Cancer Research UK Cambridge Institute, Cambridge, UK., Chhabra A; Radiopharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Wilkinson IB; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Laustsen C; Department of Clinical Medicine, Aarhus University MR Research Centre, Aarhus, Denmark., Brindle K; Cancer Research UK Cambridge Centre, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK., McLean MA; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK., Gallagher FA; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK. |
| Source: | Magnetic resonance in medicine [Magn Reson Med] 2025 Sep; Vol. 94 (3), pp. 1202-1217. Date of Electronic Publication: 2025 May 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 8505245 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-2594 (Electronic) Linking ISSN: 07403194 NLM ISO Abbreviation: Magn Reson Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
